CytoDyn Closes $16.5M Financing to Fund Continued Development of Leronlimab

“The successful execution of this financing demonstrates continued and strong investor support for our clinical strategy and the long-term potential of leronlimab,” said Robert E. Hoffman, CFO of CytoDyn. “We are encouraged by the continued commitment of our existing investors, as well as the strong engagement from new investors, which we believe underscores growing interest in leronlimab’s potential in immuno-oncology. With this financing expected to fund operations into the second half of 2027, we are well positioned to focus on clinical execution and the pursuit of strategic priorities that we believe will create meaningful long-term value for our shareholders.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib